Form 4: Lantern Pharma Director and 10% Owner Sells Over 40,000 Shares

A director and significant shareholder of Lantern Pharma Inc., Aaron G.L. Fletcher, along with affiliated Bios funds, reported the sale of 40,000 shares of common stock on June 13, 2025, at a weighted average price of $3.09 per share.

Summary

• Aaron G.L. Fletcher, a Director and 10% Owner of Lantern Pharma Inc. (LTRN), along with several affiliated Bios funds, reported the sale of common stock.
• The transactions occurred on June 13, 2025, at a weighted average price of $3.09 per share, with prices ranging from $3.05 to $3.26.
• Bios Fund I QP, LP sold 7,206 shares, retaining 189,117 shares beneficially owned.
• Bios Fund I, LP sold 12,319 shares, retaining 323,335 shares beneficially owned.
• Bios Fund II NT, LP sold 1,903 shares, retaining 49,957 shares beneficially owned.
• Bios Fund II QP, LP sold 14,218 shares, retaining 373,178 shares beneficially owned.
• Bios Fund II, LP sold 4,354 shares, retaining 114,272 shares beneficially owned.
• In total, 40,000 shares of common stock were disposed of across these entities.
• Following these transactions, the Bios Equity Entities collectively beneficially own 1,075,952 shares of common stock, including 26,093 shares held by BP Directors, LP.
• This Form 4 is the first of two filings related to the same event, necessitated by the SEC's EDGAR system limit of 10 reporting persons per form; the second will be filed by Leslie W. Kreis.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the insider selling activity by a director and significant shareholder, which can be interpreted as a lack of confidence or a belief that the stock is overvalued.

Negatives

• A significant sale of shares by a director and 10% owner, along with affiliated funds, can be perceived as a negative signal by investors regarding the company's near-term prospects or valuation.

Future Outlook

NA

Industry Context

This filing is a standard insider transaction report and does not provide broader industry context or trends.

Related Party Transactions

• The reported transactions involve sales of common stock by Aaron G.L. Fletcher, a director and 10% owner, and various Bios funds which are affiliated entities under common management and control, thus constituting related party transactions.

Stakeholder Impact

• Shareholders may view the insider selling as a negative indicator, potentially leading to a decrease in investor confidence and share price.

Next Steps

• A second Form 4 filing related to the same event will be submitted by Leslie W. Kreis, as there were more than 10 reporting persons involved in the transactions.

Key Dates

Recommendation

Keywords

Lantern Pharma, LTRN, SEC Form 4, Insider Trading, Stock Sale, Beneficial Ownership, Aaron G.L. Fletcher, Bios Partners, Director Sale, 10% Owner